HTR5A and inflammatory bowel disease: Given that DSS alters the availability of colonic 5-HT (21, 22) and increases the expression of 5-HT7 receptors in the colon (10), pharmacological inhibition of these receptors may prevent a positive feedback loop, which promotes the dysregulated inflammatory environment common in IBD.